Le Lézard

PADCEVtm Plus KEYTRUDAtm, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as ...

Warning over fake weight loss drug being sold on social media

The fake weight loss drug, which has not been approved in any country, is being promoted by social media influencers ...

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients …

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...